Pharmacokinetic evaluation and In Vitro-In Vivo Correlation (IVIVC) of novel methylene-substituted 3,3′ diindolylmethane (DIM)

European Journal of Pharmaceutical Sciences

Volumn 46, Issue 1-2, 2012, Pages 8-16

  Patel, Apurva R ^a   Spencer, Shawn D ^a   Chougule, Mahavir B ^a   Safe, Stephen ^b   Singh, Mandip ^a  

^a FLORIDA A AND M UNIVERSITY   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Anticancer; Anticarcinogen; Chemoprevention; DIM; Pharmacokinetic model

Indexed keywords

3,3' DIINDOLYLMETHANE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; COMPARTMENT MODEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG PENETRATION; DRUG SOLUBILITY; LIPOPHILICITY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MICHAELIS MENTEN KINETICS; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANIMALS; ANTICARCINOGENIC AGENTS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; HUMANS; INDOLES; INJECTIONS, INTRAVENOUS; MALE; MODELS, BIOLOGICAL; PERMEABILITY; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY;

EID: 84859215236     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2012.01.012     Document Type: Article

References (33)

1. Abdelrahim, M., Newman, K., Vanderlaag, K., Samudio, I., Safe, S., 2006. 3,3′- Diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5. Carcinogenesis 27, 717-728.
2. Anderton, M.J., Manson, M.M., Verschoyle, R., Gescher, A., Steward, W.P., Williams, M.L., Mager, D.E., 2004. Physiological modeling of formulated and crystalline 3,3′-diindolylmethane pharmacokinetics following oral administration in mice. Drug Metab. Dispos. 32, 632-638. (Pubitemid 38668156)
3. Balimane, P.V., Han, Y.H., Chong, S., 2006. Current industrial practices of assessing permeability and P-glycoprotein interaction. AAPS J. 8, E1-E13.
4. Chang, X., Tou, J.C., Hong, C., Kim, H.A., Riby, J.E., Firestone, G.L., Bjeldanes, L.F., 2005. 3,3′-Diindolylmethane inhibits angiogenesis and the growth of transplantable human breast carcinoma in athymic mice. Carcinogenesis 26, 771-778. (Pubitemid 41214339)
5. Chen, X., Murawski, A., Patel, K., Crespi, C.L., Balimane, P.V., 2008. A novel design of artificial membrane for improving the PAMPA model. Pharm. Res. 25, 1511-1520.
6. Davis, J.L., Little, D., Blikslager, A.T., Papich, M.G., 2006. Mucosal permeability of water-soluble drugs in the equine jejunum: a preliminary investigation. J. Veterinary Pharmacol. Ther. 29, 379-385. (Pubitemid 44337692)
7. Gustafson, D.L., Long, M.E., Zirrolli, J.A., Duncan, M.W., Holden, S.N., Pierson, A.S., Eckhardt, S.G., 2003. Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay. Cancer Chemother. Pharmacol. 52, 159-166. (Pubitemid 37041350)
8. Ichite, N., Chougule, M.B., Jackson, T., Fulzele, S.V., Safe, S., Singh, M., 2009. Enhancement of docetaxel anticancer activity by a novel diindolylmethane compound in human non-small cell lung cancer. Clin. Cancer Res. 15, 543-552.
9. Ichite, N., Chougule, M.B., Patel, A.R., Jackson, T., Safe, S., Singh, M., 2010. Inhalation delivery of anovel diindolylmethane derivative for the treatment of lung cancer. Mol. Cancer Ther. 9, 3003-3014.
10. Jellinck, P.H., Forkert, P.G., Riddick, D.S., Okey, A.B., Michnovicz, J.J., Bradlow, H.L., 1993. Ah receptor binding properties of indole carbinols and induction of hepatic estradiol hydroxylation. Biochem. Pharmacol. 45, 1129-1136. (Pubitemid 23079991)
11. Jusko, W.J., 1980. Guidelines for collection and pharmacokinetic analysis of drug disposition data. In: Evans, W.E., S., J.J., Jusko, W.J. (Eds.), Applied Pharmacokinetics. Applied Therapeutics, Inc., San Francisco.
12. Kansy, M., Senner, F., Gubernator, K., 1998. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. J. Med. Chem. 41, 1007-1010. (Pubitemid 28207375)
13. Karlsson, P.A.a.J., 1991. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun. 175, 880-885.
14. Konsoula, R., Barile, F.A., 2007. Correlation of in vitro cytotoxicity with paracellular permeability in mortal rat intestinal cells. J. Pharmacol. Toxicol. Methods 55, 176-183. (Pubitemid 46237745)
15. Koolen, S.L., Oostendorp, R.L., Beijnen, J.H., Schellens, J.H., Huitema, A.D., 2010. Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer. Br. J. Clin. Pharmacol. 69, 465-474.
16. Leeson, P.D., Springthorpe, B., 2007. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discov. 6, 881-890. (Pubitemid 350042396)
17. Lei, P., Abdelrahim, M., Cho, S.D., Liu, S., Chintharlapalli, S., Safe, S., 2008. 1,1-Bis(3′- indolyl)-1-(p-substituted phenyl)methanes inhibit colon cancer cell and tumor growth through activation of c-jun N-terminal kinase. Carcinogenesis 29, 1139-1147. (Pubitemid 351958692)
18. Lei, P., Abdelrahim, M., Safe, S., 2006. 1,1-Bis(30-indolyl)-1-(p- substituted phenyl)methanes inhibit ovarian cancer cell growth through peroxisome proliferator-activated receptor-dependent and independent pathways. Mol. Cancer Ther. 5, 2324-2336. (Pubitemid 44530470)
19. Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J., 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3-26. (Pubitemid 33653411)
20. Nachshon-Kedmi, M., Fares, F.A., Yannai, S., 2004. Therapeutic activity of 3,3′- diindolylmethane on prostate cancer in an in vivo model. Prostate 61, 153-160. (Pubitemid 39244702)
21. Ng, C.M., Patnaik, A., Beeram, M., Lin, C.C., Takimoto, C.H., 2010. Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients. Cancer Chemother. Pharmacol. 67 (5), 985-994.
22. Panchagnula, R., Thomas, N.S., 2000. Biopharmaceutics and pharmacokinetics in drug research. Int. J. Pharm. 201, 131-150.
23. Polli, J.E., Ginski, M.J., 1998. Human drug absorption kinetics and comparison to Caco-2 monolayer permeabilities. Pharm. Res. 15, 47-52. (Pubitemid 28080865)
24. Qin, C., Morrow, D., Stewart, J., Spencer, K., Porter, W., Smith 3rd, R., Phillips, T., Abdelrahim, M., Samudio, I., Safe, S., 2004. A new class of peroxisome proliferator-activated receptor gamma (PPARgamma) agonists that inhibit growth of breast cancer cells: 1,1-Bis(3′-indolyl)-1-(p- substituted phenyl)methanes. Mol. Cancer Ther. 3, 247-260.
25. Reed, G.A., Arneson, D.W., Putnam, W.C., Smith, H.J., Gray, J.C., Sullivan, D.K., Mayo, M.S., Crowell, J.A., Hurwitz, A., 2006. Single-dose and multiple-dose administration of indole-3-carbinol to women: pharmacokinetics based on 3,30-diindolylmethane. Cancer Epidemiol. Biomarkers Prev. 15, 2477-2481. (Pubitemid 46048308)
26. Reed, G.A., Sunega, J.M., Sullivan, D.K., Gray, J.C., Mayo, M.S., Crowell, J.A., Hurwitz, A., 2008. Single-dose pharmacokinetics and tolerability of absorption-enhanced 3,3′-diindolylmethane in healthy subjects. Cancer Epidemiol. Biomarkers Prev. 17, 2619-2624.
27. Safe, S., Papineni, S., Chintharlapalli, S., 2008. Cancer chemotherapy with indole-3- carbinol, bis(3′-indolyl)methane and synthetic analogs. Cancer Lett. 269, 326-338.
28. Sugano, K., Nabuchi, Y., Machida, M., Aso, Y., 2003. Prediction of human intestinal permeability using artificial membrane permeability. Int. J. Pharm. 257, 245-251. (Pubitemid 36507050)
29. Testa, B., Crivori, P., Reist, M., Carrupt, P.A., 2000. The influence of lipophilicity on the pharmacokinetic behavior of drugs: Concepts and examples. Perspect. Drug Discovery Des. 19.
30. Tetko, I.V., Bruneau, P., 2004. Application of ALOGPS to predict 1-octanol/water distribution coefficients, logP, and logD, of AstraZeneca in-house database. J. Pharm. Sci. 93, 3103-3110. (Pubitemid 39657814)
31. Vanderlaag, K., Su, Y., Frankel, A.E., Grage, H., Smith 3rd, R., Khan, S., Safe, S., 2008. 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes inhibit proliferation of estrogen receptor-negative breast cancer cells by activation of multiple pathways. Breast Cancer Res. Treat. 109, 273-283. (Pubitemid 351644847)
32. Wagner, J.G., 1983. Pharmacokinetic absorption plots from oral data alone or oral/ intravenous data and an exact Loo-Riegelman equation. J. Pharm. Sci. 72, 838-842. (Pubitemid 13076427)
33. Yamashita, S., Kaneda, K., Han, T.H., 2010. Population pharmacokinetics of apropofol bolus administered in patients with major burns. Burns. 36 (8), 1215-1221.